Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B) filed its Monthly Return for Equity Issuer for the month ended 31 July 2026, indicating no movements in authorised, issued or treasury shares during the period.

Authorised/Registered Capital • Total authorised share capital stood unchanged at 456.82 million ordinary shares with a par value of RMB 1 each. • This total comprises 420.29 million H shares listed on the Hong Kong Stock Exchange and 36.53 million unlisted domestic shares.

Issued Share Capital and Treasury Shares • Issued share capital mirrored the authorised figures at 456.82 million shares. • No treasury shares were recorded, and there were no repurchases, cancellations or redemptions during the month.

Public Float • The company affirmed compliance with the Main Board’s minimum public float requirement of 25 percent for its H-share class as of 31 July 2026.

Capital-Raising Instruments • The return reported no outstanding share options, warrants, convertible securities, or other agreements that could dilute existing share capital. • There were no Hong Kong Depositary Receipts (HDRs) in issue.

The unchanged capital structure underscores the company’s stable equity position through July 2026, with regulatory float thresholds fully satisfied.